Pharma Mar (BME:PHM) Faces An Earnings Test As Investors Weigh Its Valuation

Pharma Mar (BME:PHM) is back in focus after reporting first half 2026 earnings, with net income of €0.561 million compared with €19.42 million for the same period a year earlier.

See our latest analysis for Pharma Mar.

Pharma Mar's recent half year net income figure has come alongside a 10.81% 1 month share price return to €81.0. However, the share price is still down 15.62% over three months, while the 3 year total shareholder return of 149.26% remains strong. This suggests momentum has cooled in the short term even as long term holders have seen substantial gains.

If this earnings move has you rethinking your watchlist, it can be useful to widen the search to other healthcare opportunities, including companies using AI in medicine through the Simply Wall St screener for 127 healthcare AI stocks

So is Pharma Mar’s recent pullback after a weak half year result a clearer mirror of the underlying earnings power, or just a swing in sentiment around a stock that has rewarded long term holders? And what does the current valuation suggest?

Most Popular Narrative: 35.2% Undervalued

The most followed narrative on Pharma Mar compares a fair value of €125 to the latest close at €81, framing the stock as meaningfully discounted and heavily driven by expectations around its oncology portfolio.

PharmaMar's differentiated focus on marine-derived oncology compounds uniquely positions it to capitalize on the global trend toward personalized medicine and rising cancer incidence, enabling long-term premium pricing and sustainable revenue expansion as patient and prescriber demand migrates toward novel therapeutics not easily replicated by competitors.

Read the complete narrative. Read the complete narrative.

Want to understand why some analysts see room between Pharma Mar's current share price and that €125 fair value? The narrative focuses on ambitious revenue growth, expanding profit margins and a future earnings multiple that assumes the market will treat this oncology pipeline very differently to today.

Result: Fair Value of €125 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Pharma Mar still faces concentration on a handful of oncology drugs and rising competition that could pressure royalties, pricing power and the positive valuation narrative.

Find out about the key risks to this Pharma Mar narrative.

Another View on Pharma Mar’s Valuation

The SWS DCF model paints a very different picture for Pharma Mar. At a share price of €81, the stock is assessed as trading about 81.7% below an estimated future cash flow value of €443.34. That flags a large gap. Is this a genuine opportunity or a sign that expectations are too aggressive?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With mixed signals around Pharma Mar's earnings and valuation, it makes sense to test the optimism against the concerns yourself and not rely on headlines alone. To see which issues investors flag as risks and which factors they treat as potential upsides, start by reviewing the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Pharma Mar?

If you are reassessing Pharma Mar after these results, it can be useful to compare it with other ideas that match your risk and income preferences.

• Target potential value opportunities by comparing Pharma Mar with companies flagged in the 248 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by reviewing stocks in the 304 resilient stocks with low risk scores.
• Add potential income streams by scanning companies featured in the 439 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com